Neurology:影响WHO II级脑胶质瘤术后妊娠妇女长期生存的因素

2022-04-28 Naomi MedSci原创

患WHO II级胶质瘤(GIIG)的妇女常困惑于怀孕对肿瘤预后的影响。研究发现,肿瘤残留量和肿瘤生长速度是制约GIIG患者孕后长期生存的有力预测因素,识别风险患者对有受孕计划GIIG妇女至关重要。

得益于对世卫组织II级胶质瘤(GIIG)采取了积极的治疗策略,特别是依赖于早期最大安全手术,患者预期寿命现在显著延长,最近一系列的总生存期(OS)超过16年。此外,患者生活质量基本保持不变,使正常的家庭、社会和专业活动得以开展。因此,GIIG患者希望进行越来越多的长期人生规划,包括生孩子。然而,当前尚存在争议,若干研究表明怀孕可能会促进胶质瘤的进展和早期临床恶化。然而,除了这些研究是回顾性的之外,还结合了GIIG和高级别胶质瘤、混合了诊断时和诊断后怀孕的患者,并包括经治疗和未治疗的患者,且没有详细说明产后的长期随访。

近日,研究人员连续报告了一系列同种诊断的女性患者,她们在手术切除GIIG后怀孕,在怀孕前未进行肿瘤治疗,且健康状况稳定,即肿瘤没有或生长缓慢、没有对比剂增强、癫痫得到控制。基于围孕期临床放射学预后和妊娠后相关的长期肿瘤学预后的分析,研究人员试图寻找生存的预测因素,以便识别处于危险中的患者,并相应地建议GIIG妇女有成为母亲的愿望。

纳入标准为GIIG切除后已怀孕且怀孕时肿瘤状态稳定(没有正在进行的肿瘤治疗、没有对比剂增强、没有衰弱的临床情况)的成年妇女。相关案例是从其科手术切除的组织学证实的GIIG患者的数据库(1998-2021年)中发现。

  • 345例GIIG育龄妇女(年龄<45岁)中,妊娠16例(4.6%,平均分娩年龄30.9±5.1岁),其中2次妊娠5例。
  • 最后一次肿瘤治疗(11例单纯手术,5例化疗和/或放射治疗)到怀孕的平均间隔为3.5年(0.75-10年)。两名患者在怀孕期间癫痫发作。除1例(1例剖腹产)外,其余均为阴道分娩。所有儿童都有正常的心理和身体发育。
  • 7例(43.7%)患者的行为发生改变,直径扩张速度(VDE)加快和/或在孕期或孕后3个月内出现对比剂增强,7例在产后早期接受治疗和/或再次手术。
  • 分娩后的中位临床随访期为5.3年(1.25~11.6年)。另外4名患者接受了胶质瘤进展的延迟辅助治疗。7例(43.7%)死亡,中位分娩时间为3.9年(1.25-5.9年)。总体而言,分娩后的中位生存期为5.75年。
  • 至关重要的是,接受过完全手术切除的患者和怀孕前病变稳定的患者的寿命更长(对数等级,分别为p=0.046和p=0.0026)。

肿瘤残留量和肿瘤生长速度是制约GIIG患者孕后长期生存的有力预测因素。识别有风险的患者对于向渴望成为母亲的GIIG妇女提供相关咨询至关重要。

文献来源:Ng S, Duffau H. Factors Associated With Long-term Survival in Women Who Get Pregnant After Surgery for WHO Grade II Glioma [published online ahead of print, 2022 Apr 11]. Neurology. 2022;10.1212/WNL.0000000000200523. doi:10.1212/WNL.0000000000200523

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001797, encodeId=6fb82001e97d7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 07:43:45 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215280, encodeId=5924121528092, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Apr 28 12:12:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215211, encodeId=7053121521124, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu Apr 28 06:57:29 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618349, encodeId=ee9b161834990, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Apr 27 08:43:45 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-07-05 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001797, encodeId=6fb82001e97d7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 07:43:45 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215280, encodeId=5924121528092, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Apr 28 12:12:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215211, encodeId=7053121521124, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu Apr 28 06:57:29 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618349, encodeId=ee9b161834990, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Apr 27 08:43:45 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-04-28 仁术2021

    不错,学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2001797, encodeId=6fb82001e97d7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 07:43:45 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215280, encodeId=5924121528092, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Apr 28 12:12:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215211, encodeId=7053121521124, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu Apr 28 06:57:29 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618349, encodeId=ee9b161834990, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Apr 27 08:43:45 CST 2022, time=2022-04-27, status=1, ipAttribution=)]
    2022-04-28 1064510_1039
  4. [GetPortalCommentsPageByObjectIdResponse(id=2001797, encodeId=6fb82001e97d7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 07:43:45 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215280, encodeId=5924121528092, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Thu Apr 28 12:12:52 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215211, encodeId=7053121521124, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu Apr 28 06:57:29 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618349, encodeId=ee9b161834990, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Wed Apr 27 08:43:45 CST 2022, time=2022-04-27, status=1, ipAttribution=)]

相关资讯

European Radiology:多参数z谱MRI对临床患者胶质瘤分层的价值

胶质瘤是中枢神经系统中最常见的原发性脑肿瘤,与高残疾率和高死亡率有关。胶质瘤患者的总体存活率很低,即使在手术切除后再进行辅助放射化学治疗也是如此。

Clin Cancer Res:FGFR抑制剂Infigratinib单药治疗携带EGFR变异的复发性胶质瘤的疗效

携带 FGFR1 或 FGFR3 点突变以及 FGFR3-TACC3 融合变异的患者可从 Infigratinib 单药治疗中获得持久的疾病控制

拓展阅读

European Radiology:基于深度学习的T2-FLAIR错配信号量化IDH突变成人型弥漫性低级别胶质瘤

低级别胶质瘤(LGGs),是一组高度异质性的肿瘤,可依据其不同的分子和病理特征进行分类。根据 2021 年 WHO 脑肿瘤分类,遗传信息对于精准诊断弥漫性低级别胶质瘤患者并制定个体化治疗方案愈发重要。

European Radiology:增强MRI在胶质瘤的长期监测中有多大价值?

目前,关于在胶质瘤患者的长期随访中是否以及何时停止使用 GBCA,尚无基于证据的指南。此前也没有研究探讨过,仅根据这些患者 T2w 上的异常是否可以确定肿瘤进展,而不会导致诊断延迟。

European Radiology:放射组学用于区分放射性脑损伤和胶质瘤复发的系统回顾及分析

影像组学通过从医学图像中提取大量特征并转化为高维数据,能从常规医学图像中捕捉肿瘤的空间异质性,揭示非影像组学方法可能遗漏的隐藏信息。

Nature:脑肿瘤免疫治疗为何屡屡碰壁?研究人员破解髓系细胞“四副面孔”

《Nature》研究发现胶质瘤微环境中髓系细胞携四套基因程序,在促癌与抗癌间切换,导致免疫治疗失效。研究解析程序特征、空间分布,揭示治疗陷阱,提出靶向细胞程序的新治疗策略。

华南理工大学附属第二医院杨蕊梦/袁友永团队Biomaterials:免疫/代谢双调控的胞外靶点纳米递药体系助力胶质瘤免疫治疗

本研究开发了一种胞外靶点药物递送策略,利用肿瘤微环境响应性生物正交原位组装的纳米载体递送免疫调节药物,解决了传统胞内递药策略制约膜上靶点药物在胞外发挥作用的难题。

述评|光明与挑战:胶质瘤靶向治疗前沿进展

近年来,越来越多的靶向药物被用于胶质瘤的临床治疗,为患者提供了丰富的个性化治疗策略。然而,由于血脑屏障的存在、肿瘤微环境的复杂性、组织异质性以及药物耐受性等问题,胶质瘤的治疗仍面临严峻挑战。

2024 EANO指南:成人胶质瘤,胶质神经元瘤和神经元肿瘤用于靶向治疗选择的合理分子检测

欧洲神经肿瘤协会(EANO,European Association for Neuro-Oncology) · 2024-10-10

胶质瘤化疗中国专家共识

暂未更新 · 2024-08-25

SEOM-GEINO 2 级胶质瘤临床指南(2023 年)

西班牙肿瘤内科学会 (SEOM) · 2024-04-26